The uTRACE platform is being developed to improve the diagnosis of certain types of cancer. Credit: Michal Jarmoluk from Pixabay.

Curasight and Curium have agreed to develop and commercialise the former’s uTRACE positron emission tomography (PET) imaging technology for use in prostate cancer.

Both entities have signed an exclusive global licence and collaboration agreement in this regard.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the deal, Curasight will be responsible for the development of the uTRACEtechnology for use in prostate cancer with the aim of obtaining regulatory approval in the European Union (EU) and the US.

Curium will be tasked with the commercial production of uTRACE, as well as the commercialisation of the product across the world.

Curasight will receive up to $70m after the achievement of development and commercial milestones related to the product.

Furthermore, the company will be entitled to receive double-digit percentage royalties on product sales in major markets upon successful commercialisation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Curasight’s objective is to establish uTRACE as a pioneering PET tracer, offering an alternative or supplement to conventional biopsies for use in assessing patients undergoing active surveillance for prostate cancer.

Curasight CEO Ulrich Krasilnikoff said: “Our collaboration pairs Curasight’s strengths in the development of uTRACE and Curium’s proven expertise, capacity, and global track record in the manufacturing and commercialisation of radiopharmaceuticals.

“This partnership supports further development of our diagnostic platform, bringing us closer to fulfilling our ambition of helping a large number of prostate cancer patients.”

The uTRACEplatform forms part of Curasights uPAR theranostic solution, which is a combination of targeted radionuclide therapy and non-invasive PET imaging.

The theranostic solution includes the uTREATtargeted treatment technology and the uTRACEdiagnostic technology.

The main objective of the uTRACE platform is to improve the diagnosis of certain types of cancer including prostate cancer. It enables the provision of personalised treatment solutions for each patient.

Multiple Phase II clinical trials have validated the efficacy of this technology.